NovoCure Limited Price Today
NovoCure Limited
NVCR
Healthcare
$1.52B
💰
Market Cap
0
💸
Price to Earnings
$-1.9
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
5 |
Strong Buy |
3 |
Hold |
5 |
Sell |
0 |
Strong Sell |
0 |
NVCR Price Forecast Target
14.2 👉 42.0 +196%
NVCR EPS Forecast
-1.9 👉 -1.8 +-6%
Financials
Profit Margin
-41 %
Revenue Growth
4.2 %
Dividend
$ 0
Held Percent
1.7% - Insiders
85.9% - Institutions
12.4% - Public
Major Fund Holders
-
💰 FMR, LLC $226.4M
-
💰 Vanguard Group Inc $138.4M
-
💰 Capital International Investors $125.7M
-
💰 Blackrock Inc. $124.7M
-
💰 Baillie Gifford and Company $68.6M
Stock Ideas
Andreas Halvorsen Portfolio
Andreas Halvorsen is a Norwegian billionaire investor, hedge fund manager, and the founder of Viking Global Investors, a large hedge fund with over $50 billion in assets under management. He is known for his long-term, value-oriented investment appr…
Daniel Sundheim Portfolio
Daniel Sundheim is the founder of D1 Capital Partners, a renowned multi-billion dollar global investment firm. Prior to starting his own firm, Sundheim worked as a portfolio manager at prestigious hedge funds before breaking out on his own in 2018. …
David Shaw Portfolio
David Shaw is a renowned computer scientist, technological pioneer, and founder of D.E. Shaw Group, one of the earliest quantitative hedge funds. Shaw pioneered the use of algorithmic and computational modeling in institutional investing. While litt…
David Einhorn Portfolio
David Einhorn is one of the most successful long/short equity hedge fund managers of the past decade. As of July 2013, David Einhorn’s Greenlight Capital has returned 19.5% since its inception in 1996. Greenlight Capital’s market beta is around 0.5,…📮FAQ
Some Frequently Asked Questions.
The NovoCure Limited industry is Medical Devices
The NovoCure Limited sector is Healthcare
The NovoCure Limited forecasted predicted Price to Earnings PE ratio is -7.7
The NovoCure Limited Price to Earnings PE ratio is 0
The Market Capitalization of NovoCure Limited is $1.52B
There are total of 95915020 float shares with 85.9% held by Institutions and 1.7% held by insiders
The MNovoCure Limited forecasted Earnings per Share EPS is $-1.8
The NovoCure Limited Earnings per Share EPS is -1.9
The NovoCure Limited company has $0 gross profits with -41 profit margins
The NovoCure Limited Earnings Growth is 0% with 0% quarterly earnings growth
The NovoCure Limited Revenue is $509337984 with 0.042 revenue growth
The price target for NovoCure Limited stock is $42.0 for the high target and $15.0 for the low target
The consensus analyst recommendations for NovoCure Limited is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for NovoCure Limited is Buy, with the following breakdown:
- Buy: 5
- Strong Buy: 3
- Hold: 5
- Sell: 0
- Strong Sell: 0
The Beta of NovoCure Limited is 0.4
The dividend of NovoCure Limited is $0
The dividend yield of NovoCure Limited is 0%
The biggest institutional and mutual fund holders of NovoCure Limited stock are
- FMR, LLC
- Vanguard Group Inc
- Capital International Investors
- Blackrock Inc.
The NovoCure Limited ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0